Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12620000683932
Ethics application status
Approved
Date submitted
24/04/2020
Date registered
15/06/2020
Date last updated
28/07/2024
Date data sharing statement initially provided
15/06/2020
Type of registration
Prospectively registered

Titles & IDs
Public title
Testing efficacy of Breath Pearls for management of bad breath associated with a very low calorie diet (VLCD)
Scientific title
Can compliance with VLCD be improved using Breath Pearls to manage halitosis: a prospective double blinded randomised controlled trial
Secondary ID [1] 301120 0
Nil known
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Halitosis 317213 0
Condition category
Condition code
Oral and Gastrointestinal 315354 315354 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
The intervention will begin in the second week of the VLCD, either soft-gel capsules of peppermint oil (Breath Pearls™) or placebo. Two capsules will be taken orally three times a day (after meals). The placebo and active treatments will be identical in packaging and delivery.
Bottle of Breath Pearls/placebo will be collected by the study nurse on the morning of surgery to assess compliance for counting of the remaining capsules
Intervention code [1] 317429 0
Treatment: Other
Comparator / control treatment
The placebo treatment is composed of sunflower oil
Control group
Placebo

Outcomes
Primary outcome [1] 323612 0
Change in halitosis rating as assessed by change in HALT questionnaire score
Timepoint [1] 323612 0
2 weeks after commencement of Very low calorie diet
Secondary outcome [1] 382349 0
Any change in gastro intestinal quality of life questionnaire score
Timepoint [1] 382349 0
The gastro intestinal quality of life questionnaire will be administered at the commencement of VLCD (0) time point, the end of week 1 and the end of week 2
Secondary outcome [2] 382350 0
Compliance with VLCD assessed by measuring urine ketones the morning of surgery
Timepoint [2] 382350 0
2 weeks after the commencment of VLCD,
Secondary outcome [3] 382351 0
Measuring weight change from the commencement of VLCD to weight following 2 weeks of VLCD. Weight will be measured using the same digital weighing scales
Timepoint [3] 382351 0
2 weeks post commencement of VLCD

Eligibility
Key inclusion criteria
Patients will be considered for inclusion if they are planned for bariatric surgery and on a VLCD.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
• will not accept the randomisation process;
• have medical issues which contraindicate the application of either arm of the study such as acute myocardial infarction within the past 6 months, dementia, bulimia, active psychosis, concurrent experimental drug use, current pregnancy, lactation, illicit drug use, excessive alcohol intake, use of drugs known to affect body composition, cytotoxic drugs, internal malignancy, or major organ failure;
• are unable to understand the risks, realistic benefits and compliance requirements of the interventions.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
The random assignment of eligible patients will be computer generated by the Monash University School of Public Health and Preventative Medicine (SPHPM) data centre which employs this type of system for all major trials.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
A telephone based system will be established which will allow a check of patent eligibility and randomisation only proceed if the patient meets the criteria. Randomisation will be clustered into blocks of between 6 and 8 to ensure even distribution.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
. For the primary endpoint, a 95% CI for the difference in proportions between groups will be inspected and equivalence will be declared if the ends of the CI both fall within the equivalence margin (-5%, +5%). If necessary, a secondary set of analyses will be performed to adjust for baseline characteristics that are found to be imbalanced between groups where imbalance is pre-specified as a 0.25 standard deviation difference in means (quantitative measures) or an odds ratio of 1.5 (binary measures). Multivariate analysis will be performed using multiple logistic regression for binomial outcomes adjusting for baseline imbalances and potential covariates. Data analysis will be completed by an independent statistician who will be blinded to the allocation of groups. We will analyze by Intent to Treat, Last Observation Carried Forwards (ITT LOCF), Observed case and by Completer analysis, to give estimates of the effect size based on each of these scenarios.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
3/08/2020
Actual
5/11/2020
Date of last participant enrolment
Anticipated
31/01/2021
Actual
12/04/2021
Date of last data collection
Anticipated
14/02/2021
Actual
12/05/2021
Sample size
Target
40
Accrual to date
Final
40
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment postcode(s) [1] 30119 0
3144 - Malvern
Recruitment postcode(s) [2] 30120 0
3181 - Windsor

Funding & Sponsors
Funding source category [1] 305563 0
Commercial sector/Industry
Name [1] 305563 0
Myerton Australia PTY LTD
Country [1] 305563 0
Australia
Primary sponsor type
University
Name
Monash University
Address
Professor Wendy Brown
Department of Surgery
The Alfred Centre
99 Commercial Rd
Melbourne 3004 Victoria
Country
Australia
Secondary sponsor category [1] 305970 0
None
Name [1] 305970 0
Address [1] 305970 0
Country [1] 305970 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 305869 0
Ramsay Health Research Governance Committeee
Ethics committee address [1] 305869 0
Ethics committee country [1] 305869 0
Australia
Date submitted for ethics approval [1] 305869 0
21/07/2020
Approval date [1] 305869 0
28/08/2020
Ethics approval number [1] 305869 0
HREC Reference number 2020-006

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 101874 0
Mr Paul Burton
Address 101874 0
Department of Surgery
Level 6 The Alfred Centre
99 Commercial Rd
Melbourne 3004 Victoria
Country 101874 0
Australia
Phone 101874 0
+61 3 99030190
Fax 101874 0
+61 3 99030717
Email 101874 0
[email protected]
Contact person for public queries
Name 101875 0
Paul Burton
Address 101875 0
Department of Surgery
Level 6 The Alfred Centre
99 Commercial Rd
Melbourne 3004 Victoria
Country 101875 0
Australia
Phone 101875 0
+61 3 99030190
Fax 101875 0
+61 3 99030717
Email 101875 0
[email protected]
Contact person for scientific queries
Name 101876 0
Paul Burton
Address 101876 0
Department of Surgery
Level 6 The Alfred Centre
99 Commercial Rd
Melbourne 3004 Victoria
Country 101876 0
Australia
Phone 101876 0
+61 3 99030190
Fax 101876 0
+61 3 99030717
Email 101876 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
Deidentified data including weight , Questionnaire scores, and level of compliance using urine ketosis measurements
When will data be available (start and end dates)?
Staring immediately following publication with no end date
Available to whom?
Anyone who wishes to access it
Available for what types of analyses?
Any purpose
How or where can data be obtained?
Data can be obtained by emailing the principal investigator, [email protected]


What supporting documents are/will be available?

Doc. No.TypeCitationLinkEmailOther DetailsAttachment
7766Study protocol  [email protected]
7767Statistical analysis plan  [email protected]
7768Informed consent form  [email protected]
7769Clinical study report  [email protected]
7770Ethical approval  [email protected]



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.